Spark Therapeutics (NASDAQ:ONCE) had a weak trading session and its shares were last down at $46.13, down -0.12% or -0.26 points. The trading data also revealed that the total net flow stood at $1.61 million as the shares had $4.64 million in upticks but lost $3.03 million in downticks. The up/down ratio was 1.53. This data is particularly important for the traders and speculators alike as it could also be used to gauge the strength of the momentum in the shares. During the past week, the shares have seen a change of 0.81% in the shares.The block trade data suggests an inflow of $0.93 million in upticks and an outflow of $0 million in downticks. The up/down ratio for the block stood at 0. The net money flow for this transaction was recorded at $0.93.
The stock has recorded a 20-day Moving Average of 11.52% and the 50-Day Moving Average is 7.95%. The company shares have dropped 30.19% in the past 52 Weeks. On July 23, 2015 The shares registered one year high of $71.75 and one year low was seen on February 9, 2016 at $21.2. The 50-day moving average is $45.98 and the 200 day moving average is recorded at $38.05. S&P 500 has rallied 1.93% during the last 52-weeks.
Spark Therapeutics (NASDAQ:ONCE): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $47.16 and $45.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $47.72. The buying momentum continued till the end and the stock did not give up its gains. It closed at $46.56, notching a gain of 0.67% for the day. The total traded volume was 592,751 . The stock had closed at $46.25 on the previous day.
Currently the company Insiders own 9.6% of Spark Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -7.14% . Institutional Investors own 70.62% of Spark Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -1.85%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Marrazzo Jeffrey D, director officer (Chief Executive Officer) of Spark Therapeutics, Inc., had unloaded 5,000 shares at an average price of $47.26 in a transaction dated on June 15, 2016. The total value of the transaction was worth $236,300.
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Sparks product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Companys product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.